Research Reports


Home » Reports » Hepatitis B Therapeutic Drug Market Global Demand Analysis Opportunity Outlook 2021
Market Research Report

Hepatitis B Therapeutic Drug Market : Global Demand Analysis & Opportunity Outlook 2021

Published On : 11:52 PM, 25th April, 2018 REP-ID-57 Category: Healthcare

Hepatitis B, a leading cause of human mortalities across the globe, is a fatal disease which leads to infections in the liver. A person suffering from Hepatitis B needs proper and intensive care which is provided through various therapeutic drugs of Hepatitis B available in the market.

Global hepatitis B therapeutic drug market was valued at approximately USD 3.2 Billion in 2014 and is anticipated to foster at a modest compound annual growth rate (CAGR) of 2.6% over the forecast period i.e. 2015-2021. Geographically, the market is segmented into North America, Latin America, Western and Eastern Europe, Asia-Pacific and Rest of World. Asia-Pacific hepatitis B therapeutic market is envisioned to behold the fastest growth in coming 5-6 years.

Market Segmentation

By Products

On the basis of products, the global hepatitis B therapeutic drug market is segmented into:

  • Baraclude
  • Pegasys
  • Tyzeka
  • Baraclude
  • Hepsera
  • Others

By Demography

Global hepatitis B therapeutic drug market can be segmented based on demography

  • Male
  • Female

By Types

Based on the patents, the global hepatitis B market is divided into

  • Generic Drugs  
  • Branded Drugs

Growth Drivers and challenges

Increasing incidences of Hepatitis B, rising government and non-government organizations’ initiatives to promote use of hepatitis drugs are believed to drive the global hepatitis B therapeutic drug market over the forecast period.

However, high cost of hepatitis B drugs and complex regulatory procedures are likely to dampen the growth of the market in future.

Market Size and Forecast

North America dominates the global hepatitis B therapeutic drug market in the world. The hepatitis B drug market in North America is sparked by higher spending of government on healthcare industry. The U.S. and Canada are two major markets of hepatitis B drugs in North America. The U.S. Hepatitis B drug market is likely to get fostered by increasing immigration of hepatitis B patients from emerging nations.

Europe is also expected to account for a larger share of the global hepatitis B therapeutic drug market during the forecast period. The market is likely to get propelled by rising incidence of various types of hepatitis in some of the major countries such as Germany, Spain, Italy, U.K., France, and Hungary.

Asia-Pacific hepatitis B therapeutic drug market is forecasted to have the highest growth rate owing to increasing healthcare infrastructure in countries such as India and China. In addition to that, increase in aging population in japan is further expected to boost the hepatitis B therapeutic drug market in the region.

Key Players

The global hepatitis B therapeutic drug market includes some of the top players such as GlaxoSmithKline, Bristol-Myers Squibb Company, Mitsubishi Tanabe Pharma Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Merck & Co. Inc., Novartis AG, AbbVie Inc., etc.                                        

Scope and Context

Overview of the Parent Market

Analyst View

Market Size and Growth

  • North America
  • Latin America
  • Western and Eastern Europe
  • Asia-Pacific
  • Rest of World


  • By Products
  • By Demography

Market Dynamics

Supply & Demand Risk

Competitive Landscape

Porter’s Five Force Model

Geographical Economic Activity

Key Players (respective SWOT Analysis) and their Strategies and Product Portfolio

Recent Trends and Developments

Industry Growth Drivers and Challenges

Key Information for Players to establish themselves in current dynamic environment


    • "This is an ongoing research and would be delivered in next 15-20 days."
    • Pre-Book now and get receive 10% discount.



    Direct access to analyst to help you understand the market in a better way to handle your critical question


    Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved


    Get 10% free customization


    Great focus on accuracy and quality of the research

Request for Toc

Call us

(U.S.) - +1 646 586 9123
(Canada) - +1 437 889 3230
(U.K.) - +44 203 608 5919
(India) - + 91 120 660 5495

Ask The Analyst

Delivery Center

Ansal Corporate Park, Plot no 7A/1,
Tower A1,
Sector 142 Noida., 201301 India

US Office

77 Water Street 8th Floor,
New York, New York, 10005
Phone : +1 646 586 9123

Canada (Toronto)

Phone : +1 437 889 3230

UK Office (London)

Phone : +44 203 608 5919

Copyright © 2018 Research Nester. All rights reserved